Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Rhea-AI Summary
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on retina treatments, has scheduled its Q2 2025 earnings conference call for Tuesday, August 5, 2025, at 8:00 AM ET. The company will discuss its business progress and financial results for the quarter ended June 30, 2025.
The call will be accessible via U.S. dial-in (1-877-407-9039), international dial-in (1-201-689-8470), and webcast. A replay will be available on the company's Investor Relations page for at least 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OCUL declined 2.73%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025.
Conference Call and Webcast Information:
Date: Tuesday, August 5, 2025, at 8:00 AM ET
Participant Dial-In (U.S.): 1-877-407-9039
Participant Dial-In (International): 1-201-689-8470
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) reporting Q2 2025 earnings?
How can investors access OCUL's Q2 2025 earnings call?
What period will Ocular Therapeutix's earnings report cover?
How long will OCUL's Q2 2025 earnings webcast be available?
